Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin (CLASS15)
Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial.
Sponsor: Canadian Diabetes Association
This NA trial investigates Type1diabetes and is currently completed. Canadian Diabetes Association leads this study, which shows 10 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2021 — Jul 2024 [monthly]
Completed NA
Status: Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Recruiting NA
-
Oct 2019 — Dec 2019 [monthly]
Recruiting NA
-
Nov 2018 — Oct 2019 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Not Yet Recruiting NA
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Canadian Diabetes Association
- Institut de Recherches Cliniques de Montreal
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
For direct contact, visit the study record on ClinicalTrials.gov .